Literature DB >> 18065495

p21-activated kinase 1 promotes soluble mutant huntingtin self-interaction and enhances toxicity.

Shouqing Luo1, Haruo Mizuta, David C Rubinsztein.   

Abstract

Huntington's disease (HD) is caused by a polyglutamine (polyQ) expansion in the huntingtin (htt) protein. While aggregation is a pathological hallmark of HD and related polyQ expansion diseases, the role of aggregates has been disputed. Here we report that p21-activated kinase 1 (Pak1) binds to htt in vivo and in vitro. Pak1 colocalized with mutant htt (muhtt) aggregates in cell models and in human HD brains. Pak1 overexpression enhanced the aggregation of muhtt. Furthermore, we observed SDS-soluble wild-type htt (wthtt)-wthtt, wthtt-muhtt and muhtt-muhtt interactions, which were enhanced by the presence of Pak1. We show that Pak1 overexpression enhanced htt toxicity in cell models and neurons in parallel with its ability to promote aggregation, while Pak1 knockdown suppressed both aggregation and toxicity. Overexpression of either kinase-dead or wild-type Pak enhanced both aggregation and toxicity. Our data reveal a novel mechanism regulating muhtt oligomerization and toxicity and suggest that pathology may be at least partly dependent on soluble muhtt-muhtt interactions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18065495     DOI: 10.1093/hmg/ddm362

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  23 in total

Review 1.  PAK1 as a therapeutic target.

Authors:  Julia V Kichina; Anna Goc; Belal Al-Husein; Payaningal R Somanath; Eugene S Kandel
Journal:  Expert Opin Ther Targets       Date:  2010-07       Impact factor: 6.902

2.  Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice.

Authors:  Danielle A Simmons; Rishi A Mehta; Julie C Lauterborn; Christine M Gall; Gary Lynch
Journal:  Neurobiol Dis       Date:  2010-10-23       Impact factor: 5.996

3.  Expression of p21-activated kinases 1 and 3 is altered in the brain of subjects with depression.

Authors:  Beata Fuchsova; Anabel Alvarez Juliá; Hooriyah S Rizavi; Alberto Carlos Frasch; Ghanshyam N Pandey
Journal:  Neuroscience       Date:  2016-07-27       Impact factor: 3.590

4.  Infection of primary neurons mediated by nipah virus envelope proteins: role of host target cells in antiviral action.

Authors:  Aparna Talekar; Antonello Pessi; Matteo Porotto
Journal:  J Virol       Date:  2011-06-08       Impact factor: 5.103

5.  Huntingtin interacts with the cue domain of gp78 and inhibits gp78 binding to ubiquitin and p97/VCP.

Authors:  Hui Yang; Chao Liu; Yongwang Zhong; Shouqing Luo; Mervyn J Monteiro; Shengyun Fang
Journal:  PLoS One       Date:  2010-01-26       Impact factor: 3.240

6.  Do PAKs make good drug targets?

Authors:  Zhuo-Shen Zhao; Ed Manser
Journal:  F1000 Biol Rep       Date:  2010-09-23

7.  PAK1 regulates ATXN1 levels providing an opportunity to modify its toxicity in spinocerebellar ataxia type 1.

Authors:  Vitaliy V Bondar; Carolyn J Adamski; Tarik S Onur; Qiumin Tan; Li Wang; Javier Diaz-Garcia; Jeehye Park; Harry T Orr; Juan Botas; Huda Y Zoghbi
Journal:  Hum Mol Genet       Date:  2018-08-15       Impact factor: 6.150

8.  PAK in Alzheimer disease, Huntington disease and X-linked mental retardation.

Authors:  Qiu-Lan Ma; Fusheng Yang; Sally A Frautschy; Greg M Cole
Journal:  Cell Logist       Date:  2012-04-01

9.  Wild-type but not mutant huntingtin modulates the transcriptional activity of liver X receptors.

Authors:  M Futter; H Diekmann; E Schoenmakers; O Sadiq; K Chatterjee; D C Rubinsztein
Journal:  J Med Genet       Date:  2009-05-17       Impact factor: 6.318

10.  Huntingtin promotes cell survival by preventing Pak2 cleavage.

Authors:  Shouqing Luo; David C Rubinsztein
Journal:  J Cell Sci       Date:  2009-02-24       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.